Titan Medical Inc. Announces Filing of Prospectus Supplement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN
THE UNITED STATES


Titan Medical Inc. ("Titan" or the "Company") (TSX VENTURE:TMD)(OTCQX:TITXF) is
pleased to announce that it has today filed a prospectus supplement (the
"Prospectus") to the Company's short form base shelf prospectus dated October
15, 2012, regarding its previously announced public offering of units of the
Company ("Units"). Each Unit consists of one common share ("Share") of the
Company and one Share purchase warrant ("Warrant"). Each Warrant entitles the
holder thereof to acquire one Share at a price of $2.75 for a period of 36
months following the Closing Date (as defined below).


Dundee Securities Ltd. (the "Agent") has agreed to sell, on a best efforts
agency basis and, pursuant to the terms and conditions of an agency agreement
dated April 10, 2014 between the Company and the Agent (the "Agency Agreement"),
10,611,469 Units at a price of $2.10 per Unit (the "Offering") for total gross
proceeds of $22,284,085. The Agent has been granted the option to offer for sale
up to an additional 15% of the Units issued under the Offering, exercisable in
whole or in part on the Closing Date or at any time up to 30 days following the
Closing Date. BayFront Capital Partners Ltd. is acting as a selling group member
in connection with the Offering.


The Offering is scheduled to close on or about April 23, 2014 (the "Closing
Date"). The Offering is subject to a number of conditions, including, without
limitation, receipt of all regulatory approvals.


The Securities offered have not been registered under the U.S. Securities Act of
1933, as amended, and may not be offered or sold in the United States absent
registration or an applicable exemption from the registration requirements. This
press release shall not constitute an offer to sell or the solicitation of an
offer to buy nor shall there be any sale of the Securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful.


For further details regarding the Offering, please see the Company's press
release dated April 7, 2014, the Prospectus and the Agency Agreement, copies of
which are available under the Company's profile at www.sedar.com.


About Titan Medical Inc.

Titan Medical Inc. is a Canadian public company focused on the design and
development of a robotic surgical system for application in minimally invasive
surgery ("MIS"). The Company's Single Port Orifice Robotic Technology, SPORT(TM)
Surgical System, currently under development, comprises a surgeon-controlled
robotic platform that includes a 3D vision system and interactive instruments
for performing MIS procedures, and a surgeon workstation that provides the
surgeon with an interface to the robotic platform for controlling the
interactive instruments and providing a 3D endoscopic view of inside a patient's
body during MIS procedures. The SPORT(TM) Surgical System is being designed to
expand robotic surgery into areas of surgical specialties and simple and complex
procedures that are currently under-serviced, and to allow surgeons to perform
procedures within small to medium size surgical spaces such as general surgery
and cholecystectomy. For more information, visit the Company's website at
www.titanmedicalinc.com.


Forward-Looking Statements

This news release contains "forward-looking statements" which reflect the
current expectations of management of the Company's future growth, results of
operations, performance and business prospects and opportunities. Wherever
possible, words such as "may", "would", "could", "will", "anticipate",
"believe", "plan", "expect", "intend", "estimate", "potential for" and similar
expressions have been used to identify these forward-looking statements. These
statements reflect management's current beliefs with respect to future events
and are based on information currently available to management. Forward-looking
statements involve significant risks, uncertainties and assumptions. Many
factors could cause the Company's actual results, performance or achievements to
be materially different from any future results, performance or achievements
that may be expressed or implied by such forward-looking statements, including,
without limitation, those listed in the "Risk Factors" section of the Company's
Annual Information Form dated April 4, 2014 (which may be viewed at
www.sedar.com). Should one or more of these risks or uncertainties materialize,
or should assumptions underlying the forward looking statements prove incorrect,
actual results, performance or achievements may vary materially from those
expressed or implied by the forward-looking statements contained in this news
release. These factors should be considered carefully and prospective investors
should not place undue reliance on the forward-looking statements. Although the
forward-looking statements contained in the news release are based upon what
management currently believes to be reasonable assumptions, the Company cannot
assure prospective investors that actual results, performance or achievements
will be consistent with these forward-looking statements.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Titan Medical Inc.
John Hargrove
Chairman and Chief Executive Officer
[phone] (ext. 151)
[e-mail]
www.titanmedicalinc.com


Beverly Brooks
Investor Relations
[phone]
[e-mail]